NSE
AMBUJACEM
BSE
500425
ISIN
INE079A01024

AMBUJACEM

₹359.90

−₹1.95 (−0.54%)

NSE close ·

AMBUJACEM closed at ₹359.90 on 21 Oct 2026, down 0.54% on the day, and is down 36.36% over the past year.

52-week range38.9% below high
₹341.00₹588.75
TodayVolume 12.04 L
₹353.00₹362.15

Price history

Between 23 Oct 2025 and 21 Oct 2026, the closing price ranged from ₹341.00 to ₹577.20.

Price returns, excl. dividends. 3Y, 5Y and Max are annualised.

Fundamentals

P/E (TTM)
20.4
EPS (TTM)
₹17.66
Dividend yield
0.56%

EPS over the four quarters to 30 Jun 2026 (consolidated). Dividend yield is the past year’s dividends over the latest close.

Armor risk check

AMBUJACEM moves about 2× as much as the market

Volatility, past year

AMBUJACEM29%
Nifty 50015%

Worst fall, past year

AMBUJACEM−41%
Nifty 500−15%

Compared with the Nifty 500 over the past 12 months.

Check it against your portfolio in the app

FAQs

What is AMBUJACEM's share price today?

AMBUJACEM (NSE: AMBUJACEM) closed at ₹359.90 on 21 Oct 2026, down 0.54% from the previous close of ₹361.85. It traded between ₹353.00 and ₹362.15 that day.

What are AMBUJACEM's 52-week high and low?

Over the last 52 weeks AMBUJACEM traded between ₹341.00 and ₹588.75, adjusted for splits and bonuses.

What are AMBUJACEM's NSE symbol, BSE code and ISIN?

AMBUJACEM has NSE symbol AMBUJACEM, BSE code 500425, ISIN INE079A01024.

How has AMBUJACEM performed over 1, 3 and 5 years?

AMBUJACEM's share price return: 1Y −36.36%, 3Y −5.82% a year, 5Y −1.08% a year. Dividends are not included.

Does AMBUJACEM pay a dividend?

Yes. AMBUJACEM's latest dividend went ex on 12 Jun 2026: Final · ₹2.00 per share. Dividends over the past year come to a yield of 0.56% at the latest close.

What is AMBUJACEM's P/E ratio?

AMBUJACEM's P/E ratio is 20.4: the ₹359.90 close on 21 Oct 2026 over trailing twelve-month EPS of ₹17.66 (consolidated, four quarters to 30 Jun 2026).

For information only. Not investment advice or a research report. Past performance does not guarantee future returns.

Full disclaimer

See how AMBUJACEM fits your plan

Armor checks every holding against your goals, risk and timeline.

Get the app